27-Feb-2026
No press releases found.
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
TipRanks (Fri, 27-Feb 1:27 PM ET)
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
TipRanks (Tue, 24-Feb 2:19 PM ET)
Market Chameleon (Thu, 20-Nov 6:51 AM ET)
XBI Bullish Call Spread is Undervalued at $4.25
Market Chameleon (Tue, 9-Apr 7:04 AM ET)
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.
State Street SPDR S&P Biotech ETF trades on the ARCA stock market under the symbol XBI.
As of February 27, 2026, XBI stock price declined to $127.37 with 5,548,746 million shares trading.
XBI has a beta of 0.94, meaning it tends to be less sensitive to market movements. XBI has a correlation of 0.40 to the broad based SPY ETF.
XBI has a market cap of $8.34 billion. This is considered a Mid Cap stock.
In the last 3 years, XBI traded as high as $132.09 and as low as $63.80.
XBI has outperformed the market in the last year with a price return of +46.7% while the SPY ETF gained +18.5%. XBI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.0% and +3.7%, respectively, while the SPY returned +1.2% and +0.6%, respectively.
XBI support price is $125.31 and resistance is $130.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBI shares will trade within this expected range on the day.